Vector-borne diseases are a significant and growing public health concern. They account for approximately 20% of infectious diseases globally and cause more than 700,000 deaths each year. These diseases are caused by viral, bacterial, or parasitic pathogens most commonly transmitted through the bites of infected mosquitoes and ticks. In the United States, emerging viral infections include West Nile, dengue, chikungunya, and Zika; emerging bacterial infections include human monocytic ehrlichiosis, human granulocytic anaplasmosis, and Rocky Mountain spotted fever. Bacterial infections often require early recognition and prompt treatment with doxycycline. Increasing incidence of vector-borne diseases is closely linked with environmental changes, climate shifts, urbanization, and increased interaction with vector habitats. Preventive strategies include minimizing skin exposure with appropriate clothing, using insecticide-treated bed nets, and applying insect repellents containing 20% to 30% N, N-diethyl-m-toluamide (DEET) or 20% picaridin. Applying permethrin to clothing provides additional protection. Because many vectors are active during the day—particularly Aedes mosquitoes and most ticks—protective measures should extend beyond nighttime exposure.
See related editorial.
Vector-borne diseases are caused by viral, bacterial, or parasitic pathogens transmitted through bites, most commonly mosquitoes and ticks. Globally, vector-borne diseases account for approximately 20% of infectious diseases and cause more than 700,000 deaths each year.1 Emerging and reemerging vector-borne diseases, defined as those gaining prevalence or with rapidly expanding geographic distribution, are a significant and growing public health concern.2
In the past 20 years, environmental changes, climate shifts, and the development of previously uninhabited regions has led to the rapid emergence of vector-borne diseases (eg, West Nile virus, Zika virus) in the Western Hemisphere2 (Table 13–9). The increasing range of human activity, driven by population growth, deforestation, and expanded access to recreational activities such as camping and adventure tourism, has also made exposure and infection more likely.10 Additional vector-borne diseases not discussed in this article are listed in eTable A. Malaria (transmitted by the Anopheles mosquito) was the focus of a previous American Family Physician article and is not included in this review.11
TABLE 1. Emerging Vector-Borne Diseases in North America
| Disease | Region | Incubation period | Treatment | Vector | Clinical presentation | Rash description | Notes |
|---|---|---|---|---|---|---|---|
| Mosquito-borne viruses | |||||||
| West Nile3 | Endemic in all 48 contiguous states | 2–14 days | Supportive care; oral and intravenous hydration with antipyretic therapies | Culex mosquito | Flulike symptoms (eg, fever, headache, muscle weakness, arthralgia) and rash | Maculopapular on trunk, arms, and legs | Neuroinvasive disease (eg, meningitis, encephalitis, acute flaccid paralysis) occurs in < 1% of infections but has significant morbidity |
| Dengue4 | Southern United States; tropical climates (American Samoa, Puerto Rico, US Virgin Islands) | 4–7 days | Supportive care | Aedes mosquito | High fever, severe myalgia and arthralgia, rash, bleeding; dengue hemorrhagic fever can also occur | Erythematous and confluent with islands of unaffected skin; petechiae may be present around sites of compression | Dengvaxia is the only vaccine available in the United States; however, the manufacturer has stopped production citing low demand |
| Chikungunya5 | Southern United States; tropical climates | 3–7 days | Supportive care | Aedes mosquito | High fever, severe arthralgia, rash, headache | Maculopapular | The live vaccine (IXCHIQ; not available in the United States) may be administered to those ≥ 18 years traveling to endemic areas for cumulative 6 months or those > 65 years with underlying medical conditions; the recombinant vaccine (Vimkunya) is approved for those ≥ 12 years who are traveling to an endemic area Persistent, debilitating joint pain lasting weeks to months after initial infection is common Can also spread via blood transfusions and handling of blood products |
| Zika6 | Southern United States; tropical climates | 3–14 days | Supportive care | Aedes mosquito | Flulike symptoms (eg, fever, arthralgia, nonpurulent conjunctivitis) and rash | Maculopapular | Most cases (80%) are asymptomatic Complications include Guillain-Barré syndrome, encephalopathy, myelitis, uveitis, and thrombocytopenia Can be sexually transmitted by men and may cause birth defects |
| Tick-borne | |||||||
| Rocky Mountain spotted fever (Rickettsia rickettsii)7 | United States, especially southeast and central states | 3–12 days | Doxycycline, 100 mg twice daily, for 7–10 days | American dog tick (Dermacentor variabilis) Rocky Mountain wood tick (D andersoni) |
Flulike symptoms (eg, fever, headache, nausea) and rash | Maculopapular; affects whole body and can include palms and soles | Rash usually starts 2–4 days after fever Early initiation of doxycycline is critical; delays can lead to severe disease and increased mortality |
| Human monocytic ehrlichiosis (Ehrlichia chaffeensis)8 | Southeastern and south central United States | 5–14 days | Doxycycline, 100 mg twice daily, for a minimum 10 days | Lone Star tick (Amblyomma americanum) | Flulike symptoms (eg, fever, headache, chills) | Maculopapular | Leukopenia and thrombocytopenia are hallmarks |
| Human granulocytic anaplasmosis (Anaplasma phagocytophilum)9 | Northeast and Mid-Atlantic United States | 5–10 days | Doxycycline, 100 mg twice daily, for a minimum of 10 days | Deer tick (Ixodes scapularis) | Flulike symptoms (eg, fever, headache, chills) | — | Leukopenia and thrombocytopenia; elevated liver enzymes |
Read the full article
Get immediate access, anytime, anywhere.
Choose a single article, issue, or full-access subscription.
Earn up to 14 CME credits per issue.
